ADReCS

Pharmaceutical Information

Drug Name	Crizotinib
Drug ID	BADD_D00535
Description	Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
Indications and Usage	Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
Marketing Status	approved
ATC Code	L01ED01
DrugBank ID	DB08865
KEGG ID	D09731
MeSH ID	D000077547
PubChem ID	11626560
TTD Drug ID	D03ZBT
NDC Product Code	68724-1020; 53869-2231; 53869-2230; 0069-8140; 0069-8141
UNII	53AH36668S
Synonyms	Crizotinib \| PF-02341066 \| PF-2341066 \| PF 2341066 \| PF2341066 \| PF 02341066 \| PF02341066 \| Xalkori

Chemical Information

Molecular Formula	C21H22Cl2FN5O
CAS Registry Number	877399-52-5
SMILES	CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Retinal detachment	12.01.04.004; 06.09.03.003	0.000280%
Sarcoma	16.33.01.002; 15.09.03.002	0.000112%		Not Available
Sciatica	17.10.03.001; 15.10.01.001	0.000246%		Not Available
Second primary malignancy	16.16.01.014	0.001343%
Sepsis	11.01.11.003	-	-
Septic shock	24.06.02.011; 11.01.11.004	-	-	Not Available
Shock	24.06.02.002	-	-	Not Available
Sinus bradycardia	02.03.03.009	0.000616%
Skin disorder	23.03.03.007	-	-	Not Available
Small intestinal perforation	07.04.06.006	0.000112%
Squamous cell carcinoma of skin	23.08.02.005; 16.03.02.005	0.000112%		Not Available
Stomatitis	07.05.06.005	-	-
Sudden death	08.04.01.003; 02.03.04.013	0.000224%
Swelling	08.01.03.015	0.005339%		Not Available
Syncope	24.06.02.012; 02.11.04.015; 17.02.04.008	-	-
Throat irritation	22.12.03.029; 07.05.05.037	0.001198%		Not Available
Thrombocytopenia	01.08.01.002	-	-	Not Available
Tongue disorder	07.14.01.002	0.000437%		Not Available
Toothache	07.09.06.001	0.000246%
Tricuspid valve incompetence	02.07.05.001	0.000112%		Not Available
Tumour lysis syndrome	16.32.03.002; 14.05.01.004	0.000168%
Tunnel vision	17.17.01.013; 06.02.07.005	0.000112%		Not Available
Ulcer	08.03.06.001	0.000224%		Not Available
Upper respiratory tract infection	22.07.03.011; 11.01.13.009	-	-
Urethral disorder	20.07.01.002	-	-	Not Available
Urinary tract disorder	20.08.01.001	-	-	Not Available
Uterine cancer	16.12.05.001; 21.07.02.003	0.000112%		Not Available
Uveitis	10.02.01.023; 06.04.03.003	0.000168%
Vision blurred	17.17.01.010; 06.02.06.007	0.009256%
Visual acuity reduced	06.02.10.012; 17.17.01.011	0.000795%

The 8th Page First Pre 8 9 10 11 12 Next Last Total 13 Pages